Mild cognitive impairment and progression to dementia of Alzheimer's disease

Alzheimer’s Disease: Epidemiology and Clinical Progression

Alzheimer’s disease (AD) is prevalent throughout the world and is the leading cause of dementia in older individuals (aged ≥ 65 years). To gain a deeper understanding of the recent literature on the epidemiology of AD and its progression, we conducted a review of the PubMed-indexed literature (2014–2021) in North America, Europe, and Asia. The worldwide toll of AD is evidenced by rising prevalence, incidence, and mortality due to AD—estimates which are low because of underdiagnosis of AD. Mild cognitive impairment (MCI) due to AD can ultimately progress to AD dementia; estimates of AD dementia etiology among patients with MCI range from 40% to 75% depending on the populations studied and whether the MCI diagnosis was made clinically or in combination with biomarkers. The risk of AD dementia increases with progression from normal cognition with no amyloid-beta (Aβ) accumulation to early neurodegeneration and subsequently to MCI. For patients with Aβ accumulation and neurodegeneration, lifetime risk of AD dementia has been estimated to be 41.9% among women and 33.6% among men. Data on progression from preclinical AD to MCI are sparse, but an analysis of progression across the three preclinical National Institute on Aging and Alzheimer’s Association (NIA-AA) stages suggests that NIA-AA stage 3 (subtle cognitive decline with AD biomarker positivity) could be useful in combination with other tools for treatment decision-making. Factors shown to increase risk include lower Mini-Mental State Examination (MMSE) score, higher Alzheimer’s Disease Assessment Scale (ADAS-cog) score, positive APOE4 status, white matter hyperintensities volume, entorhinal cortex atrophy, cerebrospinal fluid (CSF) total tau, CSF neurogranin levels, dependency in instrumental activities of daily living (IADL), and being female. Results suggest that use of biomarkers alongside neurocognitive tests will become an important part of clinical practice as new disease-modifying therapies are introduced.

Mild cognitive impairment history and current procedures in low- and middle-income countries: a brief review

Mild cognitive impairment (MCI) is a widely studied concept that has changed over time. Epidemiology, diagnosis, costs, prognostics, screening procedures, and categorization have been extensively discussed. However, unified guidelines are still not available, especially considering differences between low- and middle-income countries (LMIC) and high-income countries (HIC).

Challenges and technologies of care developed by caregivers of patients with Alzheimer's disease

Abstract Objective: to identify the challenges and technologies of care developed by caregivers of patients with Alzheimer's disease. Method: an exploratory study with a qualitative approach was carried out with nine caregivers of elderly people with Alzheimer's disease from the mutual help group of a university hospital in the south of Brazil. Data collection took place between May and August 2017 through a semi-structured interview. Content analysis was used to analyze the data. Results: two categories emerged from the analysis of the data: the challenges faced by caregivers of elderly people with Alzheimer's Disease and the care technologies developed by caregivers of elderly people with Alzheimer's disease. Conclusion: the study showed that the care strategies elaborated by the caregiver can enhance understanding, reflection and discussion among health professionals, caregivers and family members about quality care for the elderly and minimize the difficulties of care in order to provide greater quality of care for the elderly.